Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 13/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240151 | 0.83 | SMN1; SMN2 (0.45) | HTTNPC1USP2TP53PKM | |
| SCHEMBL3243776 | 0.81 | RPS6KA3 (0.36) | MELKDYRK1ARPS6KA3 | |
| SCHEMBL3242161 | 0.78 | MET (0.43) | MELKDYRK1A | |
| SCHEMBL3245454 | 0.78 | CHRNB2 (0.43) | RIPK1 | |
| SCHEMBL3246733 | 0.75 | ALDH1A1 (0.45) | MELKHTTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3237696 | 0.73 | MELK (0.35) | MELKDYRK1A | |
| SCHEMBL3243674 | 0.72 | MAP2K7 (0.40) | — | |
| SCHEMBL3232567 | 0.71 | S1PR1 (0.41) | RIPK1 | |
| SCHEMBL3241940 | 0.71 | RPS6KA3 (0.41) | MELKDYRK1ATP53SMN1; SMN2RPS6KA3 | |
| SCHEMBL3245775 | 0.69 | SMN1; SMN2 (0.40) | NPC1USP2TP53PKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | claimed |
| WO-2009131947-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| WO-2009131947-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | CFTR, PKD1, PKD2 | MELK 3313/4885DYRK1A 2851/4885RIPK1 2466/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MELK 2699/4885DYRK1A 2818/4885RIPK1 3647/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MELK 2699/4885DYRK1A 2818/4885RIPK1 3647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.